现在时间是:
当前位置:首 页 >> PKU specialists>> English>> 文章列表

Hua Luo,M.D.

作者:pkupv   发布时间:2012-09-04 19:16:49   浏览次数:1536

 

Hua Luo, M.D. 
(086) 0755-83923333-5303,   Mail : luoxiaoer@hotmail.com
 
1. Department: Critical Care Medicine
Location: Shenzhen Hospital
No.1120, Lianhua Road,Futian District, Shenzhen, Guangdong,China
Zip Code:518036
2. Department:pulmonary vascular medicine
Location: Shenzhen Hospital
No.1120,Lianhua Road,Futian District, Shenzhen, Guangdong, China
Zip Code:518036
Specialty Interests- Pulmonary Vascular Diseases and Critical Care
 
Biographical Sketch
Doctor Hua Luo has since 2007 been devoting himself to turning pulmonary vascular medicine into an independent discipline at Peking University (PKU). He had founded the first PVD Pioneer Tribune at PKU (www.pkupv.lingd.net) without any sponsor or reward. This website has become a bridge between PKU and the overseas, reporting international developments of PVD and original scientific research at PKU. Doctor Hua Luo has established the Anticoagulation Online Clinic and offered outpatients nationwide free consultation and follow-up. He has set up an innovative theoretical framework of PVD prevention and emphasized the importance of basic education. He wrote the first PVD proposal at PKU for its discipline development and has advocated education reform for training younger colleagues on the subject, which led to the first Chinese Student Association on PVD Prevention. From 2003 to 2009, Luo had designed a series of trials to explore the individual treatment of PTE anticoagulation in China and gained the recognition from the Great Wall International Cardiovascular Conference. Based on his prospective trial in 2004, he verified 13 u/(kg·h) as the unique national heparin dosage, which was initially proposed in the retrospective study at 2003 APCDC by Professor Ying Liang. Furthermore, Luo has paid tremendous attention to PVD specialty development. He organized the first PKU working group with multi-disciplinary cooperation & the Patients Club for PVD at Shenzhen Hospital. Experts in the working group are responsible for different fields of PVD, such as diagnosis and treatment, basic research and nursing care, prevention and follow-up, international communication and cooperation, etc. Doctor Hua Luo expects to develop the Patients Club into a communication platform between doctors and patients. A lifelong follow-up for PVD patients should be established in order to improve their life quality.
 
Fellowship - Shenzhen Hospital
Pulmonary vascular Medicine
Shenzhen, Guangdong,China
2012- 2014: Associate Chief Physician
 2014-Chief Physician
Fellowship - Shenzhen Hospital
Critical Care Medicine
Shenzhen, Guangdong,China
2004---2009: Attending doctor
2009-2014: Associate Chief Physician
2014- Chief Physician
Residency – Anzhen Hospital
Pulmonary vascular Medicine 
Beijing, China.
2001---2004: Residency
University and College
1.Peking University, Health Science Center(PKU-HSC) (1993---1998)
Beijing, China.
2.Beijing Institute of cardiopulmonary vascular disease& Peking Union Medical College (PUMC) (2001-2004)
Beijing, China.

Practicing Certificates-
Internal Medicine (1999---2012)
Critical Care Medicine (2012-)
Community service-
   Fellow      Pulmonary Vascular Research Institute
Secretary     PVD center, Peking University (in building)
Secretary   Department of Critical Care Medicine, Shenzhen Hospital
Principal    PKU young scholars’ research team of PVD
Peking University Herald Tribune on Pulmonary Diseases
Academic Member        Chinese Journal of Internal Medicine.
Editorial board Member    the Journal of Cardiovascular Diagnosis and Therapy
Project Evaluation Expert     Shenzhen Science and Technology Committee,
Member          China Alliance of pulmonary hypertension and pulmonary embolism
 
Related Articles-
1 Luo H,Liang Y. Thrombin-activatable fibrinolysis inhibitor: a new modulator linking coagulation and fibrinolysis. Basic Medical Sciences and Clinics.2003; 23( 5):484-9
2 Luo H,Liang Y. The influencing factors of heparin anticoagulation guided by APTT. Journal of Cardiovascular and Pulmonary Diseases. 2003; 22(4): 245-7.
3 Luo HLiang Y. Cilinical assessment of diagnostic technology for pulmonary embolism. Chinese Journal of Medicine.2005; 40( 2):15-7
4 Luo H,Liang Y, YANG JH, et al. The study of individual dosage of warfarin and its application in pulmonary thromboembolism.Journal of Chinese Modern Medicine. 2006; 3( 5): 491-4
5 Luo H, Liang Y. Initial study of heparin dosage and the time to achieve APTT target in pulmonary thromboembolism.Journal of Cardiovascular and Pulmonary Diseases 2009;3:178-82.
6 Luo H, Liang Y. Initial Evaluation of Raschke Nomogram as Heparin Anticoagulation Guidance in Chinese Patients with Pulmonary Thromboembolism. Contemporary Medicine.2009;15(19):11-3.
7 Luo H, Liang Y. Study of relationship among heparin dosage, concentration and APTT in pulmonary thromboembolism. Journal of Cardiovascular and Pulmonary Diseases.2009;     4:269-72
 






上一篇:没有了    下一篇:没有了

Copyright ©2019    北京大学肺血管病先锋论坛 All Right Reserved.

技术支持:自助建站 | 领地网站建设 |短信接口 |燕窝 版权所有 © 2005-2019 lingw.net.粤ICP备16125321号 -5